Safety and efficacy of atezolizumab (Atezo) plus bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)

被引：0

作者：

Kuzuya, T. ^{[1
]}

Yamashita, T. ^{[2
]}

Takehara, T. ^{[3
]}

Aikata, H. ^{[4
]}

Kato, N. ^{[5
]}

Hiasa, Y. ^{[6
]}

Nakamura, S. ^{[7
]}

Morimoto, N. ^{[8
]}

Moriguchi, M. ^{[9
]}

Ikeda, M. ^{[10
]}

Inoue, J. ^{[11
]}

Tani, J. ^{[12
]}

Ueno, Y. ^{[13
]}

Chayama, K. ^{[14
]}

Tateishi, R. ^{[15
]}

Kawamura, Y. ^{[16
]}

Furuse, J. ^{[17
]}

Kudo, M. ^{[18
]}

Yamamoto, K. ^{[19
]}

Kokudo, N. ^{[20
]}

机构：

[1] Fujita Hlth Univ, Dept Gastroenterol & Hepatol, Toyoake, Aichi, Japan

[2] Kanazawa Univ, Gastroenterol Dept, Kanazawa, Ishikawa, Japan

[3] Osaka Univ, Gastroenterol & Hepatol, Suita, Osaka, Japan

[4] Hiroshima Prefectural Hosp, Gastroenterol, Minami, Japan

[5] Chiba Univ, Sch Med, Gastroenterol, Chiba, Japan

[6] Ehime Univ, Grad Sch Med, Gastroenterol & Metabol, Toon, Japan

[7] Japanese Red Cross Soc, Himeji Hosp, Internal Med, Himeji, Hyogo, Japan

[8] Jichi Med Univ Hosp, Dept Med, Div Gastroenterol, Shimotsuke, Tochigi, Japan

[9] Kyoto Prefectural Univ Med, Mol Gastroenterol & Hepatol, Kyoto, Japan

[10] Natl Canc Ctr Hosp East, Hepatobiliary & Pancreat Oncol Dept, Kashiwa, Chiba, Japan

[11] Tohoku Univ Hosp, Dept Gastroenterol, Sendai, Miyagi, Japan

[12] Kagawa Univ, Fac Med, Grad Sch Med, Dept Gastroenterol & Neurol, Miki, Kagawa, Japan

[13] Yamagata Univ, Gastroenterol, Fac Med, Yamagata, Japan

[14] Hiroshima Univ Hosp, Collaborat Res Lab Med Innovat, Hiroshima, Japan

[15] Univ Tokyo Hosp, Dept Gastroenterol, Bunkyo ku, Tokyo, Japan

[16] Toranomon Gen Hosp, Hepatol, Minato, Japan

[17] Kanagawa Canc Ctr, Dept Gastroenterol, Yokohama, Kanagawa, Japan

[18] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan

[19] Yokohama City Univ Med, Dept Biostat, Yokohama, Kanagawa, Japan

[20] NCGM Natl Ctr Global Hlth & Med, Surg, Shinjuku Ku, Tokyo, Japan

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.283

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

148P

引用

页码：S1531 / S1532

页数：2

共 50 条

[21] IMbrave150: Updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC).
Finn, Richard S.
Qin, Shukui
Ikeda, Masafumi
Galle, Peter R.
Ducreux, Michel
Kim, Tae-You
Kudo, Masatoshi
Lim, Ho Yeong
Breder, Valeriy
Merle, Philippe
Kaseb, Ahmed
Li, Daneng
Feng, Yin-Hsun
Verret, Wendy
Nicholas, Alan
Li, Lindong
Ma, Ning
Zhu, Andrew X.
Cheng, Ann-Lii
CANCER RESEARCH, 2021, 81 (13)
[22] Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
Yano, Shigeki
Kawaoka, Tomokazu
Yamasaki, Shintaro
Johira, Yusuke
Kosaka, Masanari
Shirane, Yuki
Miura, Ryoichi
Amioka, Kei
Naruto, Kensuke
Yamaoka, Kenji
Fujii, Yasutoshi
Uchikawa, Shinsuke
Fujino, Hatsue
Ono, Atsushi
Nakahara, Takashi
Murakami, Eisuke
Miki, Daiki
Tsuge, Masataka
Teraoka, Yuji
Kouno, Hirotaka
Takaki, Shintaro
Mori, Nami
Tsuji, Keiji
Oka, Shiro
CANCERS, 2023, 15 (22)
[23] Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal–gastric varices
Fujimasa Tada
Atsushi Hiraoka
Toshifumi Tada
Masashi Hirooka
Kazuya Kariyama
Joji Tani
Masanori Atsukawa
Koichi Takaguchi
Ei Itobayashi
Shinya Fukunishi
Kunihiko Tsuji
Toru Ishikawa
Kazuto Tajiri
Hironori Ochi
Hidenori Toyoda
Chikara Ogawa
Takashi Nishimura
Takeshi Hatanaka
Satoru Kakizaki
Noritomo Shimada
Kazuhito Kawata
Atsushi Naganuma
Hisashi Kosaka
Tomomitsu Matono
Hidekatsu Kuroda
Yutaka Yata
Hideko Ohama
Kazuhiro Nouso
Asahiro Morishita
Akemi Tsutsui
Takuya Nagano
Norio Itokawa
Tomomi Okubo
Taeang Arai
Keisuke Yokohama
Hiroki Nishikawa
Michitaka Imai
Yohei Koizumi
Shinichiro Nakamura
Hiroko Iijima
Masaki Kaibori
Yoichi Hiasa
Takashi Kumada
Journal of Gastroenterology, 2023, 58 : 1134 - 1143
[24] A phase II study of atezolizumab (ATEZO) and bevacizumab (Bev) in combination with Y90 TARE in patients (Pts) with hepatocellular carcinoma (HCC).
He, Aiwu Ruth
Kim, Alexander Y.
Toskich, Beau M.
Mody, Kabir
Kim, Kevin
Stein, Stacey
Goyal, Lipika
Abrams, Thomas Adam
Brown, Daniel
Goff, Laura Williams
Kim, Richard D.
Parikh, Nainesh
Sandow, Tyler
Johnson, Daniel
Iyer, Renuka V.
Petroziello, Michael
Krishnamurthi, Smitha S.
Martin, Charles
Jiang Yixing
Akhter, Nabeel
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[25] Response prediction model of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: multicenter retrospective study
Ueno, Masaki
Kosaka, Hisashi
Iida, Hiroya
Ida, Yoshiyuki
Aoi, Kazunori
Mori, Haruki
Miyamoto, Atsushi
Nishida, Yuko
Hayami, Shinya
Kawai, Manabu
Kaibori, Masaki
ONCOLOGY, 2023, 101 (09) : 565 - 574
[26] SIMILAR EFFICACY AND SAFETY BETWEEN LENVATINIB VERSUS ATEZOLIZUMAB PLUS BEVACIZUMAB FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA
Su, Chung-Wei
Teng, Wei
Lin, Po-Ting
Jeng, Wen-Juei
Chen, Kuei-An
Hsieh, Yi-Chung
Chen, Wei-Ting
Hou, Ming-Mo
Hsieh, Chia-Hsun
Lin, Chen-Chun
Lin, Chun-Yen
Lin, Hsi-Ming
HEPATOLOGY, 2022, 76 : S1415 - S1415
[27] Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non-viral infection: A Japanese multicenter observational study
Hatanaka, Takeshi
Kakizaki, Satoru
Hiraoka, Atsushi
Tada, Toshifumi
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
Ochi, Hironori
Yasuda, Satoshi
Toyoda, Hidenori
Ogawa, Chikara
Nishimura, Takashi
Shimada, Noritomo
Kawata, Kazuhito
Kosaka, Hisashi
Tanaka, Takaaki
Ohama, Hideko
Nouso, Kazuhiro
Morishita, Asahiro
Tsutsui, Akemi
Nagano, Takuya
Itokawa, Norio
Okubo, Tomomi
Arai, Taeang
Imai, Michitaka
Naganuma, Atsushi
Koizumi, Yohei
Nakamura, Shinichiro
Joko, Kouji
Kaibori, Masaki
Iijima, Hiroko
Hiasa, Yoichi
Kumada, Takashi
CANCER MEDICINE, 2023, 12 (05): : 5293 - 5303
[28] The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey
Akyildiz, Arif
Guven, Deniz Can
Ozluk, Ahmet Anil
Ismayilov, Rashad
Mutlu, Emel
Unal, Olcun Umit
Yildiz, Ibrahim
Iriagac, Yakup
Turhal, Serdar
Akbas, Sinem
Bayram, Ertugrul
Telli, Tugba Akin
Turkoz, Fatma Paksoy
Ozcelik, Melike
Erciyestepe, Mert
Selvi, Oguzhan
Gulbagci, Burcu
Erturk, Ismail
Isleyen, Zehra Sucuoglu
Kahraman, Seda
Akdag, Mutianur Ozkorkmaz
Hamitoglu, Buket
Unek, Ilkay Tugba
Unal, Caglar
Hacibekiroglu, Ilhan
Arslan, Cagatay
Azizy, Abdulmunir
Helvaci, Kaan
Demirci, Umut
Dizdar, Omer
Basaran, Mert
Goker, Erdem
Sendur, Mehmet Ali
Yalcin, Suayib
MEDICINE, 2023, 102 (45) : E35950
[29] Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal-gastric varices
Tada, Fujimasa
Hiraoka, Atsushi
Tada, Toshifumi
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
Ochi, Hironori
Toyoda, Hidenori
Ogawa, Chikara
Nishimura, Takashi
Hatanaka, Takeshi
Kakizaki, Satoru
Shimada, Noritomo
Kawata, Kazuhito
Naganuma, Atsushi
Kosaka, Hisashi
Matono, Tomomitsu
Kuroda, Hidekatsu
Yata, Yutaka
Ohama, Hideko
Nouso, Kazuhiro
Morishita, Asahiro
Tsutsui, Akemi
Nagano, Takuya
Itokawa, Norio
Okubo, Tomomi
Arai, Taeang
Yokohama, Keisuke
Nishikawa, Hiroki
Imai, Michitaka
Koizumi, Yohei
Nakamura, Shinichiro
Iijima, Hiroko
Kaibori, Masaki
Hiasa, Yoichi
Kumada, Takashi
JOURNAL OF GASTROENTEROLOGY, 2023, 58 (11) : 1134 - 1143
[30] Efficacy of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma: a Meta-analysis
Mah I Kan Changez
Maimoona Khan
Muhammad Uzair
Muhammad Fawad Tahir
Maryam Mohsin
Amna Faiyaz Hussain
Vania Saqib
Muhammad Khizer Molani
Aisha Habib Ahmed
Saad Khalid
Journal of Gastrointestinal Cancer, 2024, 55 : 467 - 481

← 1 2 3 4 5 →